Targeting thromboxane/TP and prostaglandin D2/DP2 signaling with KAR101 may reduce lung inflammation, fibrosis and cardiopulmonary dysfunction in silicosis.
Pang and colleagues tested ramatroban in silicosis model constructed by a single intratracheal instillation of 8mg silica in 40µL PBS in male C57BL/6J mice of 8-10 weeks old. Pang et al, Theranostics, 2021, doi: 10.7150/thno.47627
Ra=ramatroban; Crs=compliance of the respiratory system
RVSP=right ventricular systolic pressure; RVHI= right ventricular hypertrophy index
Ramatroban has been used for the treatment of allergic rhinitis in Japan for over 20 years, and therefore, has an excellent safety profile. Given the efficacy of ramatroban in reducing fibrosis, inflammation and cardiopulmonary dysfunction in the silicosis mouse model, we are looking to conduct clinical trials of ramatroban in patients with silicosis.
Looking for global partners to develop ramatroban (KAR101) in silicosis
Email: firstname.lastname@example.org Phone: +1 (562) 412-6259